| 前收盘价格 | 16.45 |
| 收盘价格 | 16.47 |
| 成交量 | 436,924 |
| 平均成交量 (3个月) | 452,298 |
| 市值 | 801,927,424 |
| 价格/销量 (P/S) | 75.68 |
| 股市价格/股市净资产 (P/B) | 2.44 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2026 |
| 营业利益率 (TTM) | -1,133.43% |
| 稀释每股收益 (EPS TTM) | -1.98 |
| 总债务/股东权益 (D/E MRQ) | 3.29% |
| 流动比率 (MRQ) | 13.68 |
| 营业现金流 (OCF TTM) | -53.21 M |
| 杠杆自由现金流 (LFCF TTM) | -34.85 M |
| 资产报酬率 (ROA TTM) | -19.54% |
| 股东权益报酬率 (ROE TTM) | -30.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | BioAge Labs, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
2.5
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.50 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 内部持股比例 | 3.63% |
| 机构持股比例 | 66.65% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合